Pharvaris N.V.

What they do

Pharvaris is a biopharmaceutical company focused on the development and commercialization of oral therapies for bradykinin-mediated angioedema, including hereditary angioedema (HAE). Its lead product candidates are based on a novel class of small molecule bradykinin B2 receptor antagonists, which are being developed for both on-demand treatment and prophylaxis of HAE attacks. The company is incorporated in the Netherlands and has its principal executive offices in Leiden.

Revenue drivers

• No commercial products — The company has no approved products and has not generated any revenue from product sales; it operates as a clinical-stage entity.
• Research and development funding — Operations are funded through equity offerings and other financing activities; the company has no recurring revenue sources.
• Future product candidates — Potential future revenue would come from its oral bradykinin B2 receptor antagonists for HAE, but these remain investigational and are not yet approved or commercialized.

Recent performance

The filing does not include specific financial results for the fiscal year ended December 31, 2025. As a clinical-stage company, Pharvaris has historically incurred significant research and development expenses and net losses. No revenue from product sales has been recorded. The number of outstanding common shares as of December 31, 2025 was 65,210,590.

Strategy

Pharvaris is focused on advancing its oral bradykinin B2 receptor antagonists through clinical development for HAE. The company aims to offer oral treatment options for both on-demand and prophylactic use. It plans to continue investing in research and development and to seek regulatory approvals for its product candidates. The company may also explore additional indications for its technology.

Risks

• Clinical development risk — The company's product candidates may fail in clinical trials or not receive regulatory approval, which would severely harm its business.
• No product revenue — The company has no approved products and has never generated revenue from product sales, relying on external financing to fund operations.
• Competitive landscape — The HAE market is competitive, with existing and emerging therapies that could limit the commercial potential of Pharvaris's product candidates.
• Regulatory and commercial hurdles — Even if approved, the company may face challenges in manufacturing, pricing, reimbursement, and market acceptance.

Outlook

The company's future depends on the successful clinical development and regulatory approval of its product candidates. Management has not provided specific revenue or earnings guidance. The company will require additional capital to fund its operations and may seek partnerships or financing.